We will rely on you to help lend your voice and support the biotechnology industry.
Bringing new treatments to patients, support public policies that promote innovation, improve patient access.
BIO International ConventionJune 3-6, 2019
BIO World Congress on Industrial Biotechnology and Ag TechJuly 8-11, 2019
BIO Industry Analysis Reports >>
Save. Advocate. Connect. Join Us.
A listing of all BIO members and subsidiaries.
February 11 - 12, 2019 | New York, New York
Fireside Chat: Dr. Aoife M. Brennan, President and Chief Executive Officer and Chief Medical Officer, Synlogic, Inc.
Moderator: Yi Chen, PhD, Managing Director of Equity Research, H.C. Wainwright & Co, LLC
(A) The equity research department of H.C. Wainwright & Co. covers Synlogic, Inc. with a Buy rating and $20 price target as of February 12, 2019.
(B) None of the research analysts or the research analyst’s household has a financial interest in the securities of Synlogic, Inc.
(C) As of January 31, 2019, neither H.C. Wainwright & Co. nor its affiliates beneficially own 1% or more of any class of common equity securities of Synlogic, Inc.
(D) H.C. Wainwright & Co. or its affiliates did not receive compensation from Synlogic, Inc. in the previous twelve months.
(E) None of the research analysts have received compensation from Synlogic, Inc. in the previous twelve months.
(F) Synlogic, Inc. was not a client of H.C. Wainwright & Co. or its affiliates during the previous twelve months.
(G) H.C. Wainwright & Co. does not make a market in Synlogic, Inc. as of February 12, 2019.